Cooperation of oncolytic virotherapy with VEGF-neutralizing antibody treatment in IDH wildtype glioblastoma depends on MMP9

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neuro-oncology (Charlottesville, Va.) Va.), 2019-12, Vol.21 (12), p.1607-1609
Hauptverfasser:	Wirsching, Hans-Georg, Arora, Sonali, Zhang, Huajia, Szulzewsky, Frank, Cimino, Patrick J, Quéva, Christophe, Houghton, A McGarry, Glorioso, Joseph C, Weller, Michael, Holland, Eric C
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Neutralizing - pharmacology Brain Neoplasms - genetics Brain Neoplasms - metabolism Brain Neoplasms - pathology Brain Neoplasms - therapy Combined Modality Therapy Glioblastoma - genetics Glioblastoma - metabolism Glioblastoma - pathology Glioblastoma - therapy Humans Isocitrate Dehydrogenase - genetics Letters to the Editor Matrix Metalloproteinase 9 - metabolism Mice Mutation Oncolytic Virotherapy - mortality Survival Rate Tumor Cells, Cultured Vascular Endothelial Growth Factor A - antagonists & inhibitors Vascular Endothelial Growth Factor A - immunology Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!